Translational Pathologist - IHC and Diagnostics

Bristol-Myers Squibb Translational Pathology is a growing organization comprised of a team of 1) laboratory scientists focused on immunohistochemistry (IHC) assay development and 2) pathologists who integrate histopathology data with disease mechanisms and drug mechanism of action to inform development of our pipeline.

We are seeking a Pathologist to 1) partner with our clinical and translational IHC teams to facilitate assay validation and support multiplex IHC platform development, and 2) provide programmatic support for development of companion/complementary diagnostic devices.

The role, embedded within the Translational Medicine organization, works to ensure that 1) the highest quality IHC assays are developed to support pre-clinical/clinical development and translational research, and 2) BMS diagnostic device development is supported/facilitated by pathology.

The successful candidate will work closely with (i) research scientists who discover and develop drugs for the treatment of cancer, and (ii) research scientists and clinicians who discover and develop biomarkers for pharmacodynamic assessment and patient selection strategies in Phase I-lV clinical trials. Interaction with contract research organizations and diagnostic companies will be a routine component of this role. Depending on the candidate and the availability of resources, there may be an opportunity for the individual to spend part of his or her efforts on translational research activities that have relevance to the company's business goals.

Qualifications:

• MD/PhD or MD with completion of combined anatomic pathology/clinical pathology residency required.
• Experienced pathologist with 2-5+ years' of post-graduate clinical experience in a clinical/translational setting.
• Strong skill set in developing and implementing immunohistochemistry methodologies from antibody selection and staining optimization to downstream digital and imaging strategies with data dissemination and evaluation capabilities.
• Experience with managing CRO relationships and collaborating with KOL's would be advantageous.
• Exposure to cancer immunotherapy including immune-checkpoint blockade with knowledge of current therapeutic landscape is highly desirable.
• Prior role leading scientific teams (academic or industry) in multidisciplinary projects with ability to integrate cross-functional information desired.
• Excellent interpersonal skills and ability to communicate, both written and oral effectively and efficiently within the BMS organization and with external partners/collaborators.
• Thrives in dynamic work environment, bringing a pro-active mentality to the role.